Golden
Sequence Bio

Sequence Bio

Sequence Bio is a biotechnology company combining genomic, multi-omic population data and longitudinal health records from the unique founder population of Newfoundland and Labrador, Canada to find drug targets.

All edits

Edits on 18 Aug 2019
Jed Christiansen
Jed Christiansen edited on 18 Aug 2019 10:03 pm
Edits made to:
Infobox (+2 properties)
Article

Article

Biotechnology company combining genomic, multi-omic population data and longitudinal health records from the unique founder population of Newfoundland and Labrador, Canada to find drug targets. Sequence Bio makes use of Newfoundland and Labrador’s founder population and unique history as a cohort to explore to disease preventions and treatments. This population has a high rate of complex and inherited diseases which provides an opportunity to find underlying differences that affect disease and health. Findings are expected to improve the lives of people in Newfoundland and Labrador (NL) and around the world. One of the goals is the share research findings and integrate precision into their local healthcare system. 

Infobox

Location
Company status
Active
Accelerator
Accelerator Batch
Edits on 16 Aug 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 16 Aug 2019 6:27 pm
Edits made to:
Article (+3/-3 characters)

Article

Sequence Bio is leading the NL Genome Project, a large-scale genomics research study that uses saliva samples for researching DNADNA combined with medical information in 2500 volunteers. Volunteers are enrolled at select doctor’s offices in the province. 

Will Suter
Will Suter approved a suggestion from Golden's AI on 16 Aug 2019 6:27 pm
Edits made to:
Article (+13/-13 characters)

Article

BiotechnologyBiotechnology company combining genomic, multi-omic population data and longitudinal health records from the unique founder population of Newfoundland and Labrador, Canada to find drug targets. Sequence Bio makes use of Newfoundland and Labrador’s founder population and unique history as a cohort to explore to disease preventions and treatments. This population has a high rate of complex and inherited diseases which provides an opportunity to find underlying differences that affect disease and health. Findings are expected to improve the lives of people in Newfoundland and Labrador (NL) and around the world. One of the goals is the share research findings and integrate precision into their local healthcare system. 

Will Suter
Will Suter approved a suggestion from Golden's AI on 16 Aug 2019 6:21 pm
Edits made to:
Article (+20/-20 characters)

Article

CEO Chris Gardner was appointed to the federal Health/Bio-sciences Economic Strategy Table by the Minister of Innovation, Science and Economic DevelopmentEconomic Development. CSO Michael S. Phillips previously held roles at Genomics Medicine Ireland and Merck. The company won the Community Impact and Business Excellence awards at the St. John’s Board of Trade Awards. Sequence Bio worked with Senator Jim Cowan to support passage of Bill S201 that ensures all Canadians are protected from genetic discrimination. 

Will Suter
Will Suter approved a suggestion from Golden's AI on 16 Aug 2019 6:19 pm
Edits made to:
Article (+6/-6 characters)

Article

Biotechnology company combining genomic, multi-omic population data and longitudinal health records from the unique founder population of Newfoundland and Labrador, CanadaCanada to find drug targets. Sequence Bio makes use of Newfoundland and Labrador’s founder population and unique history as a cohort to explore to disease preventions and treatments. This population has a high rate of complex and inherited diseases which provides an opportunity to find underlying differences that affect disease and health. Findings are expected to improve the lives of people in Newfoundland and Labrador (NL) and around the world. One of the goals is the share research findings and integrate precision into their local healthcare system. 

Meredith Hanel
Meredith Hanel edited on 16 Aug 2019 12:09 pm
Edits made to:
Infobox (+3 properties)
Timeline (+1 events) (+41 characters)
Description (+212/-37 characters)
Article (+1474 characters)
Documentaries, videos and podcasts (+1 rows) (+3 cells) (+109 characters)
Topic thumbnail

Sequence Bio

Drug research and development company

Sequence Bio is a biotechnology company combining genomic, multi-omic population data and longitudinal health records from the unique founder population of Newfoundland and Labrador, Canada to find drug targets.

Article

Biotechnology company combining genomic, multi-omic population data and longitudinal health records from the unique founder population of Newfoundland and Labrador, Canada to find drug targets. Sequence Bio makes use of Newfoundland and Labrador’s founder population and unique history as a cohort to explore to disease preventions and treatments. This population has a high rate of complex and inherited diseases which provides an opportunity to find underlying differences that affect disease and health. Findings are expected to improve the lives of people in Newfoundland and Labrador (NL) and around the world. One of the goals is the share research findings and integrate precision into their local healthcare system. 



CEO Chris Gardner was appointed to the federal Health/Bio-sciences Economic Strategy Table by the Minister of Innovation, Science and Economic Development. CSO Michael S. Phillips previously held roles at Genomics Medicine Ireland and Merck. The company won the Community Impact and Business Excellence awards at the St. John’s Board of Trade Awards. Sequence Bio worked with Senator Jim Cowan to support passage of Bill S201 that ensures all Canadians are protected from genetic discrimination. 



Sequence Bio is leading the NL Genome Project, a large-scale genomics research study that uses saliva samples for researching DNA combined with medical information in 2500 volunteers. Volunteers are enrolled at select doctor’s offices in the province. 

Documentaries, videos and podcasts

Title
Date
Link

Sequence Bio launches N.L. Genome Project

July 24, 2019

Infobox

Date incorporated
2013

Timeline

July 24, 2019

Sequence Bio launches N.L. Genome Project

Edits on 29 May 2019
Golden AI
Golden AI edited on 29 May 2019 2:33 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:11 pm
Edits made to:
Infobox (+3/-3 properties)
Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 12:00 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:11 am
Edits made to:
Infobox (+5 properties)
People (+13 rows) (+26 cells) (+326 characters)
Categories (+1 topics)

People

Name
Role
Related Golden topics

Chris McDonald

Employee



Dan Brake

Employee



David Phillips, CPA, CA

Employee



James Hardiman

Board member



Jeremy Grushcow, Ph.D., J.D.

Employee



John Phillips

Advisor



Mark Dobbin

Board member



Matthew Stenback

Employee



Michael Phillips

Employee



Neala Quigley

Employee



Pelorus Venture Capital Limited

Investor



Sophie Harrington

Employee



Tyler Wish

Employee



Infobox

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:48 pm
Edits on 16 Jul 2018
Golden AI"Update markets in infobox"
Golden AI edited on 16 Jul 2018 11:37 pm
Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:39 pm
Edits on 11 Jun 2018
Golden AI"Updating description"
Golden AI edited on 11 Jun 2018 7:18 pm
Edits made to:
Description (+37/-21 characters)
Topic thumbnail

Sequence Bio

Biotechnology company

Drug research and development company

Edits on 30 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 30 May 2018 10:43 pm
Edits made to:
Description (+21 characters)
People (+1 rows) (+2 cells) (+22 characters)
Categories (+1 topics)
Topic thumbnail

 Sequence Bio

Biotechnology company

People

Name
Role
Related Golden topics

Chris C Gardner

Founder



Categories

No more activity to show.